We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two PhRMA-funded surveys found that payers and providers would like more information from biopharmaceutical companies about approved and unapproved uses of medicines, including products undergoing clinical trials. Read More
The FDA should not approve generics of Glaxo Smith Kline’s asthma drug Advair Diskus that depend on multiple-batch studies to show pharmacokinetic bioequivalence, according to Mylan. Read More
Most drugmakers are fulfilling their postmarketing study commitments, but many are not meeting their deadlines for annual status reports, the FDA said. Read More
U.S. healthcare spending growth slowed in 2016, including a steep drop in spending on retail prescription drugs — decelerating after two years of faster growth associated with coverage expansions under the Affordable Care Act, according to the Centers for Medicare and Medicaid Services. Read More
ORA and CDER officials provided an update on the agency’s Concept of Operations initiative in a Thursday panel discussion at the FDLI’s Enforcement Litigation and Compliance Conference in Washington D.C., detailing the next steps in implementing the concept. Read More
An FDA advisory committee voted unanimously in favor of combining patients with bladder pain syndrome and interstitial cystitis in clinical trials citing the minimal differences in symptoms between the two populations. Read More
The FDA is planning to deliver a suite of disease-specific guidance documents next year on developing targeted gene therapies, starting with hemophilia and then more common single-gene disorders, Commissioner Scott Gottlieb told senators Thursday. Read More